49 search results for: mechanism of disease

Spotlight on Type 2 Inflammation in the Upper and Lower Airways
Pulmonology
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

View more
ADVENT On-Air Podcast: The Multifaceted Patient Burden and Drivers <b>of</b> <b>Disease</b> in Prurigo Nodularis
Dermatology
ADVENT On-Air Podcast: The Multifaceted Patient Burden and Drivers of Disease in Prurigo Nodularis
Podcast

In this episode, Dr. Sarina Elmariah and Dr. Brian Kim explore prurigo nodularis (PN), with a focus on severe itch, fibrotic skin lesions, and their impact on patients’ quality of life. They discuss PN epidemiology, common comorbidities, and the challenges of managing multimorbid patients, while breaking down the neuroimmune mechanisms, highlighting the role of type 2 cytokines in itch and lesion development.

View more
CRSwNP Triathlon: An Interactive Learning Experience
Rhinology
CRSwNP Triathlon: An Interactive Learning Experience
interactivity

Embark on this interactive triathlon challenge to uncover the interplay of type 2 inflammation, barrier dysfunction, and neuroimmune dysregulation in the disease pathology of CRSwNP.

View more
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study <b>of</b> Pediatric Patients With AD and Type 2 Comorbidities
Dermatology
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.

View more
CLCI in Atopic Dermatitis Infographic
Dermatology
CLCI in Atopic Dermatitis Infographic
Infographic

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

View more
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
Type 2 Inflammation
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.

View more
Lung Function Decline: Why it Matters and What’s at Stake for Patients
Pulmonology
Lung Function Decline: Why it Matters and What’s at Stake for Patients
interactivity

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

View more
Differential Effects <b>of</b> Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
Dermatology
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

View more
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
Congress
11
March
2024
Congress
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Neuroimmune Dysfunction Is Critical in the Pathophysiology <b>of</b> Prurigo Nodularis
Dermatology
Neuroimmune Dysfunction Is Critical in the Pathophysiology of Prurigo Nodularis
expert video

Dr. Sarina Elmariah explains the importance of neuroimmune crosstalk in the development of prurigo nodularis.

View more
The Role <b>of</b> IL-4 and IL-13 in CSU Pathogenesis
Type 2 Inflammation
The Role of IL-4 and IL-13 in CSU Pathogenesis
interactivity

Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.

View more
KOL Video Interview – Dr Paula Luna
Dermatology
KOL Video Interview – Dr Paula Luna
expert video

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

View more